ESLAW Annual EBITDA
-$7.31 M
+$3.80 M+34.23%
30 June 2024
Summary:
As of February 5, 2025, ESLAW annual earnings before interest, taxes, depreciation & amortization is -$7.31 million, with the most recent change of +$3.80 million (+34.23%) on June 30, 2024. During the last 3 years, it has fallen by -$6.58 million (-896.34%).ESLAW EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ESLAW Quarterly EBITDA
-$3.38 M
+$572.71 K+14.50%
30 September 2024
Summary:
As of February 5, 2025, ESLAW quarterly earnings before interest, taxes, depreciation & amortization is -$3.38 million, with the most recent change of +$572.71 thousand (+14.50%) on September 30, 2024. Over the past year, it has dropped by -$2.36 million (-230.85%).ESLAW Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ESLAW TTM EBITDA
-$8.82 M
-$1.51 M-20.60%
30 September 2024
Summary:
As of February 5, 2025, ESLAW TTM earnings before interest, taxes, depreciation & amortization is -$8.82 million, with the most recent change of -$1.51 million (-20.60%) on September 30, 2024. Over the past year, it has dropped by -$5.93 million (-204.95%).ESLAW TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ESLAW EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +34.2% | -230.8% | -204.9% |
| 3 y3 years | -896.3% | -230.8% | -204.9% |
| 5 y5 years | -896.3% | -230.8% | -204.9% |
ESLAW EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +896.3% | +619.2% | +219.9% |
Estrella Immunopharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.38 M(-14.5%) | -$8.82 M(+20.6%) |
| June 2024 | -$7.31 M | -$3.95 M(+741.1%) | -$7.31 M(+117.5%) |
| Mar 2024 | - | -$469.53 K(-54.0%) | -$3.36 M(+16.2%) |
| Dec 2023 | - | -$1.02 M(-45.4%) | -$2.89 M(-37.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$1.87 M(-32.1%) | -$4.63 M(+67.9%) |
| June 2023 | -$11.11 M(+559.5%) | - | - |
| Dec 2022 | - | -$2.76 M | -$2.76 M |
| June 2022 | -$1.69 M(+129.7%) | - | - |
| June 2021 | -$733.69 K | - | - |
FAQ
- What is Estrella Immunopharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Estrella Immunopharma?
- What is Estrella Immunopharma annual EBITDA year-on-year change?
- What is Estrella Immunopharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Estrella Immunopharma?
- What is Estrella Immunopharma quarterly EBITDA year-on-year change?
- What is Estrella Immunopharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Estrella Immunopharma?
- What is Estrella Immunopharma TTM EBITDA year-on-year change?
What is Estrella Immunopharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ESLAW is -$7.31 M
What is the all time high annual EBITDA for Estrella Immunopharma?
Estrella Immunopharma all-time high annual earnings before interest, taxes, depreciation & amortization is -$733.69 K
What is Estrella Immunopharma annual EBITDA year-on-year change?
Over the past year, ESLAW annual earnings before interest, taxes, depreciation & amortization has changed by +$3.80 M (+34.23%)
What is Estrella Immunopharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ESLAW is -$3.38 M
What is the all time high quarterly EBITDA for Estrella Immunopharma?
Estrella Immunopharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$469.53 K
What is Estrella Immunopharma quarterly EBITDA year-on-year change?
Over the past year, ESLAW quarterly earnings before interest, taxes, depreciation & amortization has changed by -$2.36 M (-230.85%)
What is Estrella Immunopharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ESLAW is -$8.82 M
What is the all time high TTM EBITDA for Estrella Immunopharma?
Estrella Immunopharma all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.76 M
What is Estrella Immunopharma TTM EBITDA year-on-year change?
Over the past year, ESLAW TTM earnings before interest, taxes, depreciation & amortization has changed by -$5.93 M (-204.95%)